文献速递湿疹皮炎与荨麻疹

乌帕替尼治疗中重度特应性皮炎患者相关痤疮的特征:3项3期随机双盲安慰剂对照试验的事后整合分析

Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials.
PubMed 文献 · J Am Acad Dermatol · 2022-06-15

该事后整合分析纳入3项3期随机双盲安慰剂对照试验的16周安慰剂对照期数据,评估乌帕替尼治疗中重度特应性皮炎相关痤疮。乌帕替尼15 mg组84/857例(9.8%)、30 mg组131/864例(15.2%)、安慰剂组19/862例(2.2%)发生痤疮,除1例外均为轻中度,2例因中度痤疮停药。

要点

  • 乌帕替尼15 mg组痤疮发生率9.8%,30 mg组15.2%,均高于安慰剂组2.2%。
  • 所有痤疮病例除1例外均为轻中度,仅2例因中度痤疮停药。
  • 痤疮在年轻、女性及非白人患者中发生率更高。

核心结论

  • 乌帕替尼治疗特应性皮炎相关痤疮通常为轻中度,可通过局部治疗或无需干预进行管理。

研究设计与样本

  • 3项3期随机双盲安慰剂对照试验的事后整合分析,分析16周安慰剂对照期数据。
  • 乌帕替尼单药治疗试验为NCT03569293和NCT03607422,联合局部糖皮质激素试验为NCT03568318。
  • 乌帕替尼15 mg组857例、30 mg组864例、安慰剂组862例。

主要发现

  • 16周内,乌帕替尼15 mg组84/857例(9.8%)、30 mg组131/864例(15.2%)、安慰剂组19/862例(2.2%)发生痤疮。
  • 所有痤疮病例除1例外均为轻中度;2例因中度痤疮停药。
  • 痤疮在年轻、女性及非白人患者中发生率更高。
  • 乌帕替尼15 mg组40.5%、30 mg组46.6%的痤疮无需干预;其余多数使用局部抗生素、过氧化苯甲酰和/或维A酸类管理。
  • 痤疮对患者报告结局无影响。

关键数值与推荐

  • 乌帕替尼15 mg组痤疮发生率9.8%(84/857),30 mg组15.2%(131/864),安慰剂组2.2%(19/862)。
  • 乌帕替尼15 mg组40.5%的痤疮无需干预,30 mg组46.6%无需干预。

临床怎么用

  • 乌帕替尼相关痤疮通常为轻中度,多数可通过局部抗生素、过氧化苯甲酰和/或维A酸类治疗或无需干预管理。

局限性

  • 研究持续时间相对较短。
  • 患者人群较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acne is the most frequent adverse event associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis. OBJECTIVE: To characterize the adverse event of acne associated with upadacitinib. METHODS: This was a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials of upadacitinib, alone (NCT03569293 and NCT03607422) or in combination with topical corticosteroids (NCT03568318). Data included were from the 16-week placebo-controlled period. RESULTS: Over 16 weeks, 84 of 857 (9.8%), 131 of 864 (15.2%), and 19 of 862 (2.2%) patients randomized to receive upadacitinib 15 mg, upadacitinib 30 mg, and placebo, respectively, experienced acne. All cases of acne, except 1, were mild/moderate in severity; 2 patients discontinued treatment due to moderate acne. Acne occurred at higher rates among younger, female, and non-White patients. Acne required no intervention in 40.5% and 46.6% of patients receiving upadacitinib 15 and 30 mg, respectively; most remaining cases were managed with topical antibiotics, benzoyl peroxide, and/or retinoids. Acne also had no impact on patient-reported outcomes. LIMITATIONS: This study was relatively short in duration and had a small patient population. CONCLUSIONS: Acne associated with upadacitinib for atopic dermatitis treatment is usually mild/moderate in severity and managed with topical therapies or no intervention.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022. PMID: 35714786. doi:10.1016/j.jaad.2022.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。